What effect does valproic acid have on phenytoin serum concentrations?

Valproic Acid Increases Free (Unbound) Phenytoin Levels Through Protein Displacement

Valproic acid displaces phenytoin from plasma protein binding sites, significantly increasing the free (unbound) fraction of phenytoin by 60-90%, while paradoxically decreasing or maintaining total phenytoin levels. This creates a clinically dangerous situation where standard total phenytoin monitoring becomes misleading 1.

The Biphasic Interaction Mechanism

Valproic acid exerts two opposing effects on phenytoin:

Protein Displacement (Immediate Effect):

• Increases free phenytoin fraction from approximately 10% to 15-18% 2, 3
• In some cases, free fraction increases up to 60-90% 1
• Total phenytoin levels typically decrease by 7-17% 4, 2
• Free (active) phenytoin concentrations increase by 18-25% 4, 3

Metabolic Inhibition (Secondary Effect):

• Valproic acid inhibits hepatic metabolism of phenytoin 1, 3
• This further elevates free phenytoin concentrations
• The net effect depends on which mechanism predominates

Critical Clinical Implications

The danger lies in the discordance between total and free levels:

• Total phenytoin may appear "low" or "therapeutic" (even decreasing)
• Free (active) phenytoin is actually elevated and potentially toxic
• Patients can develop phenytoin toxicity despite "normal" total levels 5

In children, the interaction is particularly pronounced:

• Serum albumin, urea, and valproic acid co-administration significantly influence unbound phenytoin fraction 6
• Pediatric patients require especially close monitoring 5

Monitoring and Management Strategy

Essential monitoring approach:

1. Measure free (unbound) phenytoin levels rather than total levels when valproic acid is co-administered 1

   • Therapeutic range for free phenytoin: 1-2 μg/mL
   • Total phenytoin monitoring is unreliable in this combination

2. Anticipate phenytoin dose reduction when adding valproic acid 1

   • Monitor for signs of phenytoin toxicity: ataxia, nystagmus, confusion, drowsiness
   • Breakthrough seizures have been reported with this combination 1

3. If free phenytoin monitoring unavailable:

   • Use albumin-based normalizing equations to predict unbound concentrations 6, 7
   • Consider empiric phenytoin dose reduction of 25% when initiating valproic acid
   • Monitor clinical response closely

Common Pitfall

The most dangerous error is increasing phenytoin dose when total levels appear low during valproic acid co-administration. This can precipitate severe toxicity because the free (active) drug is already elevated. Always assess free phenytoin levels or use clinical judgment based on toxicity symptoms rather than total drug levels 1, 4.

The FDA label explicitly warns that "dosage of phenytoin should be adjusted as required by the clinical situation" and notes reports of breakthrough seizures with this combination, emphasizing the complexity of managing these two drugs together 1.